Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management
Conventional tumor markers may serve as adjuncts in non-small cell lung cancer (NSCLC) management. This study analyzed whether three tumor markers (CEA, CA19-9, and CA-125) held associations with radiographic and clinical outcomes in NSCLC. It constituted a single-center study of NSCLC patients trea...
Gespeichert in:
| Veröffentlicht in: | Oncotarget 2024-06, Vol.15, p.381-388 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 388 |
|---|---|
| container_issue | |
| container_start_page | 381 |
| container_title | Oncotarget |
| container_volume | 15 |
| creator | Strum, Scott Vincent, Mark Gipson, Meghan McArthur, Eric Breadner, Daniel |
| description | Conventional tumor markers may serve as adjuncts in non-small cell lung cancer (NSCLC) management. This study analyzed whether three tumor markers (CEA, CA19-9, and CA-125) held associations with radiographic and clinical outcomes in NSCLC. It constituted a single-center study of NSCLC patients treated with systemic therapy at the London Regional Cancer Program. Serum tumor markers were analyzed for differences in radiographic responses (RECIST v1.1 or iRECIST), associations with clinical characteristics, and all-cause mortality. A total of 533 NSCLC patients were screened, of which 165 met inclusion criteria. A subset of 92 patients had paired tumor markers and radiographic scans. From the latter population, median (IQR) fold-change from nadir to progression was 2.13 (IQR 1.24-3.02;
< 0.001) for CEA, 1.46 (IQR 1.13-2.18;
< 0.001) for CA19-9, and 1.53 (IQR 0.96-2.12;
< 0.001) for CA-125. Median (IQR) fold-change from baseline to radiographic response was 0.50 (IQR 0.27, 0.95;
< 0.001) for CEA, 1.08 (IQR 0.74, 1.61;
= 0.99) for CA19-9, and 0.47 (IQR 0.18, 1.26;
= 0.008) for CA-125. In conclusion, tumor markers are positioned to be used as adjunct tools in clinical decision making, especially for their associations with radiographic response (CEA/CA-125) or progression (CEA/CA-125/CA-19-9). |
| doi_str_mv | 10.18632/oncotarget.28566 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11174826</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3068753277</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1556-e224fdb2ca459bf1d89be43283a372b9e184ef24b865e8fe4bf84f039273fe223</originalsourceid><addsrcrecordid>eNpVkE1PwzAMhiMEYmjsB3BBOXJYR_PVJCdUVeNDmsQFzlXaOqWjTUbTIvHv6cRAwwf7lWy_j2yErki8Iiph9Na70g-mr2FYUSWS5ARdEM11RIVgp0d6hhYhbOMpBJeK6nM0Y0rJOJb0Ark0BAihAzdgb3GAfuzwMHa-x53p36EPOFunS5ylEaFiiY2rJk10pLEJ2FTb0ZVDwI3DzrsodKZtcQlTakdX49K4EvZOztSwZ1yiM2vaAItDnaPX-_VL9hhtnh-esnQT7YgQSQSUclsVtDRc6MKSSukCOKOKGSZpoYEoDpbyQiUClAVeWMVtzDSVzE7LbI7ufnx3Y9FBVU7o3rT5rm-mq75yb5r8f8c1b3ntP3NCiOSKJpPDzcGh9x8jhCHvmrC_zDjwY8hZnCgpGJVyGr0-hv1Rfr_MvgH3rYEs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3068753277</pqid></control><display><type>article</type><title>Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Strum, Scott ; Vincent, Mark ; Gipson, Meghan ; McArthur, Eric ; Breadner, Daniel</creator><creatorcontrib>Strum, Scott ; Vincent, Mark ; Gipson, Meghan ; McArthur, Eric ; Breadner, Daniel</creatorcontrib><description>Conventional tumor markers may serve as adjuncts in non-small cell lung cancer (NSCLC) management. This study analyzed whether three tumor markers (CEA, CA19-9, and CA-125) held associations with radiographic and clinical outcomes in NSCLC. It constituted a single-center study of NSCLC patients treated with systemic therapy at the London Regional Cancer Program. Serum tumor markers were analyzed for differences in radiographic responses (RECIST v1.1 or iRECIST), associations with clinical characteristics, and all-cause mortality. A total of 533 NSCLC patients were screened, of which 165 met inclusion criteria. A subset of 92 patients had paired tumor markers and radiographic scans. From the latter population, median (IQR) fold-change from nadir to progression was 2.13 (IQR 1.24-3.02;
< 0.001) for CEA, 1.46 (IQR 1.13-2.18;
< 0.001) for CA19-9, and 1.53 (IQR 0.96-2.12;
< 0.001) for CA-125. Median (IQR) fold-change from baseline to radiographic response was 0.50 (IQR 0.27, 0.95;
< 0.001) for CEA, 1.08 (IQR 0.74, 1.61;
= 0.99) for CA19-9, and 0.47 (IQR 0.18, 1.26;
= 0.008) for CA-125. In conclusion, tumor markers are positioned to be used as adjunct tools in clinical decision making, especially for their associations with radiographic response (CEA/CA-125) or progression (CEA/CA-125/CA-19-9).</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.28566</identifier><identifier>PMID: 38870072</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Aged ; Aged, 80 and over ; Biomarkers, Tumor - blood ; CA-125 Antigen - blood ; CA-19-9 Antigen - blood ; Carcinoembryonic Antigen - blood ; Carcinoma, Non-Small-Cell Lung - blood ; Carcinoma, Non-Small-Cell Lung - diagnosis ; Carcinoma, Non-Small-Cell Lung - pathology ; Carcinoma, Non-Small-Cell Lung - therapy ; Female ; Humans ; Lung Neoplasms - blood ; Lung Neoplasms - diagnosis ; Lung Neoplasms - pathology ; Lung Neoplasms - therapy ; Male ; Middle Aged ; Research Paper</subject><ispartof>Oncotarget, 2024-06, Vol.15, p.381-388</ispartof><rights>Copyright: © 2024 Strum et al.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11174826/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11174826/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38870072$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Strum, Scott</creatorcontrib><creatorcontrib>Vincent, Mark</creatorcontrib><creatorcontrib>Gipson, Meghan</creatorcontrib><creatorcontrib>McArthur, Eric</creatorcontrib><creatorcontrib>Breadner, Daniel</creatorcontrib><title>Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Conventional tumor markers may serve as adjuncts in non-small cell lung cancer (NSCLC) management. This study analyzed whether three tumor markers (CEA, CA19-9, and CA-125) held associations with radiographic and clinical outcomes in NSCLC. It constituted a single-center study of NSCLC patients treated with systemic therapy at the London Regional Cancer Program. Serum tumor markers were analyzed for differences in radiographic responses (RECIST v1.1 or iRECIST), associations with clinical characteristics, and all-cause mortality. A total of 533 NSCLC patients were screened, of which 165 met inclusion criteria. A subset of 92 patients had paired tumor markers and radiographic scans. From the latter population, median (IQR) fold-change from nadir to progression was 2.13 (IQR 1.24-3.02;
< 0.001) for CEA, 1.46 (IQR 1.13-2.18;
< 0.001) for CA19-9, and 1.53 (IQR 0.96-2.12;
< 0.001) for CA-125. Median (IQR) fold-change from baseline to radiographic response was 0.50 (IQR 0.27, 0.95;
< 0.001) for CEA, 1.08 (IQR 0.74, 1.61;
= 0.99) for CA19-9, and 0.47 (IQR 0.18, 1.26;
= 0.008) for CA-125. In conclusion, tumor markers are positioned to be used as adjunct tools in clinical decision making, especially for their associations with radiographic response (CEA/CA-125) or progression (CEA/CA-125/CA-19-9).</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers, Tumor - blood</subject><subject>CA-125 Antigen - blood</subject><subject>CA-19-9 Antigen - blood</subject><subject>Carcinoembryonic Antigen - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnosis</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Carcinoma, Non-Small-Cell Lung - therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - pathology</subject><subject>Lung Neoplasms - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Research Paper</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkE1PwzAMhiMEYmjsB3BBOXJYR_PVJCdUVeNDmsQFzlXaOqWjTUbTIvHv6cRAwwf7lWy_j2yErki8Iiph9Na70g-mr2FYUSWS5ARdEM11RIVgp0d6hhYhbOMpBJeK6nM0Y0rJOJb0Ark0BAihAzdgb3GAfuzwMHa-x53p36EPOFunS5ylEaFiiY2rJk10pLEJ2FTb0ZVDwI3DzrsodKZtcQlTakdX49K4EvZOztSwZ1yiM2vaAItDnaPX-_VL9hhtnh-esnQT7YgQSQSUclsVtDRc6MKSSukCOKOKGSZpoYEoDpbyQiUClAVeWMVtzDSVzE7LbI7ufnx3Y9FBVU7o3rT5rm-mq75yb5r8f8c1b3ntP3NCiOSKJpPDzcGh9x8jhCHvmrC_zDjwY8hZnCgpGJVyGr0-hv1Rfr_MvgH3rYEs</recordid><startdate>20240613</startdate><enddate>20240613</enddate><creator>Strum, Scott</creator><creator>Vincent, Mark</creator><creator>Gipson, Meghan</creator><creator>McArthur, Eric</creator><creator>Breadner, Daniel</creator><general>Impact Journals LLC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240613</creationdate><title>Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management</title><author>Strum, Scott ; Vincent, Mark ; Gipson, Meghan ; McArthur, Eric ; Breadner, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1556-e224fdb2ca459bf1d89be43283a372b9e184ef24b865e8fe4bf84f039273fe223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers, Tumor - blood</topic><topic>CA-125 Antigen - blood</topic><topic>CA-19-9 Antigen - blood</topic><topic>Carcinoembryonic Antigen - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnosis</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Carcinoma, Non-Small-Cell Lung - therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - pathology</topic><topic>Lung Neoplasms - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Research Paper</topic><toplevel>online_resources</toplevel><creatorcontrib>Strum, Scott</creatorcontrib><creatorcontrib>Vincent, Mark</creatorcontrib><creatorcontrib>Gipson, Meghan</creatorcontrib><creatorcontrib>McArthur, Eric</creatorcontrib><creatorcontrib>Breadner, Daniel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strum, Scott</au><au>Vincent, Mark</au><au>Gipson, Meghan</au><au>McArthur, Eric</au><au>Breadner, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2024-06-13</date><risdate>2024</risdate><volume>15</volume><spage>381</spage><epage>388</epage><pages>381-388</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Conventional tumor markers may serve as adjuncts in non-small cell lung cancer (NSCLC) management. This study analyzed whether three tumor markers (CEA, CA19-9, and CA-125) held associations with radiographic and clinical outcomes in NSCLC. It constituted a single-center study of NSCLC patients treated with systemic therapy at the London Regional Cancer Program. Serum tumor markers were analyzed for differences in radiographic responses (RECIST v1.1 or iRECIST), associations with clinical characteristics, and all-cause mortality. A total of 533 NSCLC patients were screened, of which 165 met inclusion criteria. A subset of 92 patients had paired tumor markers and radiographic scans. From the latter population, median (IQR) fold-change from nadir to progression was 2.13 (IQR 1.24-3.02;
< 0.001) for CEA, 1.46 (IQR 1.13-2.18;
< 0.001) for CA19-9, and 1.53 (IQR 0.96-2.12;
< 0.001) for CA-125. Median (IQR) fold-change from baseline to radiographic response was 0.50 (IQR 0.27, 0.95;
< 0.001) for CEA, 1.08 (IQR 0.74, 1.61;
= 0.99) for CA19-9, and 0.47 (IQR 0.18, 1.26;
= 0.008) for CA-125. In conclusion, tumor markers are positioned to be used as adjunct tools in clinical decision making, especially for their associations with radiographic response (CEA/CA-125) or progression (CEA/CA-125/CA-19-9).</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>38870072</pmid><doi>10.18632/oncotarget.28566</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1949-2553 |
| ispartof | Oncotarget, 2024-06, Vol.15, p.381-388 |
| issn | 1949-2553 1949-2553 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11174826 |
| source | MEDLINE; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free E- Journals |
| subjects | Aged Aged, 80 and over Biomarkers, Tumor - blood CA-125 Antigen - blood CA-19-9 Antigen - blood Carcinoembryonic Antigen - blood Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Non-Small-Cell Lung - therapy Female Humans Lung Neoplasms - blood Lung Neoplasms - diagnosis Lung Neoplasms - pathology Lung Neoplasms - therapy Male Middle Aged Research Paper |
| title | Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T05%3A56%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20serum%20tumor%20markers%20CEA,%20CA-125,%20and%20CA19-9%20as%20adjuncts%20in%20non-small%20cell%20lung%20cancer%20management&rft.jtitle=Oncotarget&rft.au=Strum,%20Scott&rft.date=2024-06-13&rft.volume=15&rft.spage=381&rft.epage=388&rft.pages=381-388&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.28566&rft_dat=%3Cproquest_pubme%3E3068753277%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3068753277&rft_id=info:pmid/38870072&rfr_iscdi=true |